Provided by Tiger Trade Technology Pte. Ltd.

Warren Buffett holdings

3,184.35
+24.640.78%
Number of Gainers:22
Number of Losers:13
Number of Flat:- -
PE:- -
High:3,191.24
Open:3,159.88
Low:3,159.53
Close:3,159.71
Volume:295.92M
Turnover:37.73B
Market Cap:11.33T
Float Cap:10.77T

Loading ...

Whole Foods Market Names 10 Brands for 2026 LEAP Early Growth Cohort

Reuters
·
Sep 24

Mondelez Canada Invests in Canadian Farmers to Strengthen Agricultural Supply Chains and Advance Regenerative Agriculture

THOMSON REUTERS
·
Sep 24

Amazon (AMZN) Lures Merchants with New Perks as ‘Seller Wars’ Intensify with Walmart and eBay

TIPRANKS
·
Sep 24

Qualcomm, Apple Renew Global Patent License Agreement

Dow Jones
·
Sep 24

Citi Launches Premium Boost – Transforming How Clients are Rewarded for Their Banking Relationship

THOMSON REUTERS
·
Sep 24

Analysts Offer Insights on Financial Companies: Arthur J Gallagher & Co (AJG), Nu Holdings (NU) and Raymond James Financial (RJF)

TIPRANKS
·
Sep 24

Qualcomm Announces Renewal of Global Patent License Agreement with Apple

THOMSON REUTERS
·
Sep 24

Qualcomm - Announces Renewal of Global Patent License Agreement with Apple Effective April 1, 2027

THOMSON REUTERS
·
Sep 24

Rpt-Qualcomm - Announces Renewal of Global Patent License Agreement with Apple Effective April 1, 2027

THOMSON REUTERS
·
Sep 24

BlackBerry Lifts Annual Revenue Forecast on Strength in Automotive Software Business

Reuters
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Citi is Rolling Out Higher Rates in New Push for Clients' Assets

Dow Jones
·
Sep 24

Amazon Adds Prime Delivery Option, Discounts Fulfillment Fees for Merchants

MT Newswires Live
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

Zhaoyang District Apple Industry Drives Rural Revitalization as 2025 Harvest Boosts Comprehensive Output Value to 13.5 Billion Yuan

Deep News
·
Sep 24

Amazon Launches New AI Product, Reflecting Industry-Wide Price Cuts

Deep News
·
Sep 24